These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 25511521)

  • 21. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
    Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
    Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of hippocampal dopamine metabolism and hippocampal-dependent cognitive function by catechol-O-methyltransferase inhibition.
    Laatikainen LM; Sharp T; Bannerman DM; Harrison PJ; Tunbridge EM
    J Psychopharmacol; 2012 Dec; 26(12):1561-8. PubMed ID: 22815336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum.
    Kaakkola S; Wurtman RJ
    J Neurochem; 1993 Jan; 60(1):137-44. PubMed ID: 8417137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
    Davis TL; Roznoski M; Burns RS
    Mov Disord; 1995 May; 10(3):349-51. PubMed ID: 7651456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacological treatments of Parkinson's disease].
    Nomoto M; Iwata S; Kaseda S
    Nihon Yakurigaku Zasshi; 2001 Feb; 117(2):111-22. PubMed ID: 11233302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Central action of benserazide after COMT inhibition demonstrated in vivo by PET.
    Tedroff J; Hartvig P; Bjurling P; Andersson Y; Antoni G; Långström B
    J Neural Transm Gen Sect; 1991; 85(1):11-7. PubMed ID: 1867835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging.
    Ruottinen HM; Niinivirta M; Bergman J; Oikonen V; Solin O; Eskola O; Eronen E; Sonninen P; Rinne UK
    Synapse; 2001 Apr; 40(1):19-26. PubMed ID: 11170218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of intracerebral 6-nitronoradrenaline, an endogenous catechol-O-methyltransferase (COMT) inhibitor, on striatal dopamine metabolism in anaesthetised rats.
    Huotari M; Passlin M; Nordberg HL; Forsberg M; Kotisaari S; Tuomisto L; Shintani F; Tanaka KF; Reenilä I; Laitinen K; Männistö PT
    J Neurosci Methods; 2001 Aug; 109(1):47-52. PubMed ID: 11489299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine, locus of control, and the exploration-exploitation tradeoff.
    Kayser AS; Mitchell JM; Weinstein D; Frank MJ
    Neuropsychopharmacology; 2015 Jan; 40(2):454-62. PubMed ID: 25074639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats.
    Napolitano A; Zürcher G; Da Prada M
    Eur J Pharmacol; 1995 Feb; 273(3):215-21. PubMed ID: 7737328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.
    Gallagher CL; Christian BT; Holden JE; Dejesus OT; Nickles RJ; Buyan-Dent L; Bendlin BB; Harding SJ; Stone CK; Mueller B; Johnson SC
    Mov Disord; 2011 Sep; 26(11):2032-8. PubMed ID: 21638324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of subchronic administration of tolcapone on release of striatum dopamine and its metabolites induced by L-DOPA and carbidopa].
    Budygin EA; Gaĭnetdinov RR; Raevskiĭ KS; Mannisto PT
    Biull Eksp Biol Med; 1998 Feb; 125(2):168-71. PubMed ID: 9559129
    [No Abstract]   [Full Text] [Related]  

  • 33. Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease.
    Guay DR
    Pharmacotherapy; 1999 Jan; 19(1):6-20. PubMed ID: 9917075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional monoamine oxidase B gene intron 13 polymorphism predicts putaminal dopamine turnover in de novo Parkinson's disease.
    Löhle M; Mangone G; Wolz M; Beuthien-Baumann B; Oehme L; van den Hoff J; Kotzerke J; Reichmann H; Corvol JC; Storch A
    Mov Disord; 2018 Sep; 33(9):1496-1501. PubMed ID: 30216543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel, non-nitrocatechol catechol-O-methyltransferase inhibitors modulate dopamine neurotransmission in the frontal cortex and improve cognitive flexibility.
    Byers S; Buchler IP; DePasquale M; Rowley HL; Kulkarni RS; Pinder L; Kolobova A; Li C; Au V; Akuma D; Zhang G; Wei H; Cheetham SC; Barrow JC; Carr GV
    Psychopharmacology (Berl); 2020 Sep; 237(9):2695-2707. PubMed ID: 32474681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease.
    Chong DJ; Suchowersky O; Szumlanski C; Weinshilboum RM; Brant R; Campbell NR
    Clin Neuropharmacol; 2000; 23(3):143-8. PubMed ID: 10895397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis.
    Ishikawa T; Dhawan V; Chaly T; Robeson W; Belakhlef A; Mandel F; Dahl R; Margouleff C; Eidelberg D
    J Cereb Blood Flow Metab; 1996 Sep; 16(5):854-63. PubMed ID: 8784230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease.
    Napolitano A; Del Dotto P; Petrozzi L; Dell'Agnello G; Bellini G; Gambaccini G; Bonuccelli U
    Clin Neuropharmacol; 1999; 22(1):24-9. PubMed ID: 10047930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopamine storage capacity in caudate and putamen of patients with early Parkinson's disease: correlation with asymmetry of motor symptoms.
    Kumakura Y; Gjedde A; Danielsen EH; Christensen S; Cumming P
    J Cereb Blood Flow Metab; 2006 Mar; 26(3):358-70. PubMed ID: 16079784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Putaminal Dopamine Turnover in de novo Parkinson's Disease Predicts Later Neuropsychiatric Fluctuations but Not Other Major Health Outcomes.
    Löhle M; Hermann W; Hausbrand D; Wolz M; Mende J; Beuthien-Baumann B; Oehme L; van den Hoff J; Kotzerke J; Reichmann H; Hermann A; Storch A
    J Parkinsons Dis; 2019; 9(4):693-704. PubMed ID: 31381528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.